We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » House Calls on GAO to Assess FDA’s Regulatory Pathway for Complex Generics
House Calls on GAO to Assess FDA’s Regulatory Pathway for Complex Generics
The House Energy & Commerce Committee is calling on the GAO to evaluate whether the FDA’s regulatory pathway for generic versions of complex drugs is sufficient.